(Q35759448)

10 August 2017

title

Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence (English)

1 reference

10 August 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Marcello Dallio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Justyna Godos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Carmelina Loguercio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Federico Salomone

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

3

Justyna Godos

1 reference

10 August 2017

Alessandro Federico

1

1 reference

10 August 2017

Marcello Dallio

2

1 reference

10 August 2017

Carmela Loguercio

4

1 reference

10 August 2017

Federico Salomone

5

1 reference

10 August 2017

language of work or name

1 reference

12 August 2015

1 reference

10 August 2017

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

116-124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26318867%20AND%20SRC:MED&resulttype=core&format=json

The global NAFLD epidemic

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Pathology of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Steatohepatitis: a tale of two "hits"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Non-alcoholic fatty liver disease: need for a balanced nutritional source

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The indigenous gastrointestinal microflora

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Developmental microbial ecology of the neonatal gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Functional food concept and its application to prebiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Resistant starch and “the butyrate revolution”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Intestinal flora during the first months of life: new perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Mechanisms of Natural Tolerance in the Intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Cytokines in alcoholic and nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Ethanol oxidation and acetaldehyde production in vitro by human intestinal strains of Escherichia coli under aerobic, microaerobic, and anaerobic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Microbes and mucosa in the regulation of intracolonic acetaldehyde concentration during ethanol challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Microbiota-liver axis in hepatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Regulation of tight junction permeability by intestinal bacteria and dietary components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Epithelial crosstalk at the microbiota-mucosal interface.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Inflammation and metabolic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Origin and physiological roles of inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The liver as an immunological organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Toll-like receptors as targets in chronic liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Sorting out Toll signals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Toll-like receptors and adaptor molecules in liver disease: update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

DAMPs, PAMPs and alarmins: all we need to know about danger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Biliary lactoferrin concentrations are increased in active inflammatory bowel disease: a factor in the pathogenesis of primary sclerosing cholangitis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Diversity of the human intestinal microbial flora

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Early differences in fecal microbiota composition in children may predict overweight.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Metabolic endotoxemia initiates obesity and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The gut microbiota as an environmental factor that regulates fat storage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

TLR4 enhances TGF-beta signaling and hepatic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Update on the pathophysiology of liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Inflammation and fibrogenesis in steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

7 January 2021

Liver fibrogenic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

HMG1 and 2, and related 'architectural' DNA-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Innate immunity in alcoholic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Prognostic value of plasma endotoxin levels in patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Toll-like Receptor 4 and Hepatic Fibrogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Expression of Toll-like receptor 4 in rat liver during the course of carbon tetrachloride-induced liver injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Silencing of TGF-beta signalling by the pseudoreceptor BAMBI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Suppression of hepatic stellate cell activation by microRNA-29b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Primary biliary cirrhosis is associated with altered hepatic microRNA expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Pattern recognition receptors and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Role of TLR9 in hepatic stellate cells and experimental liver fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Neutrophils and immunity: challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Tolerance, danger, and the extended family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The sterile inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

The extracellular release of HMGB1 during apoptotic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Etiology of portal hypertension may influence gastrointestinal transit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Reticuloendothelial System Phagocytic Activity in Cirrhosis and Its Relation to Bacterial Infections and Prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Alteration of intestinal intraepithelial lymphocytes and increased bacterial translocation in a murine model of cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Intestinal permeability in cirrhotic patients with and without ascites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Probiotics--role in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Protective effect of selenium-enriched Lactobacillus on CCl4-induced liver injury in mice and its possible mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Gut-liver axis: a new point of attack to treat chronic liver damage?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.08.002